Ischemia modified albumin in experimental ovarian torsion with and without controlled reperfusion

Lazăr, Cornelia; Vozian, Marin; Pantea, Valeriana; Ana, Mișina; Tagadiuc, Olga

doi:10.2478/rrlm-2019-0008

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have reported a strong association of IMA with ischemic stroke, intracranial hemorrhage, skeletal muscle ischemia, mesenteric ischemia, peripheral atherosclerosis, hyperlipidemia, obesity, metabolic syndrome, hepatosteatosis, preeclampsia, ovarian torsion, fetal distress, β-thalassemia, diabetes, advanced renal disease and liver cirrhosis [21][22][23][24][25][26]. Serum IMA value was significantly increased in almost all the above-named cases, due to the role of the OS in the development of these diseases.…”

Section: Discussionmentioning

confidence: 97%

Study of ischemia modified albumin (IMA) as a biomarker in hypertensive retinopathy

Pavlovschi¹,

Pantea²,

Borovic³

et al. 2021

Medicine and Pharmacy Reports

Self Cite

View full text Add to dashboard Cite

Background. Hypertension (HTN) is one of the leading causes of morbidity and mortality worldwide. A prompt diagnosis and treatment of hypertensive retinopathy (HR), the leading complication of HTN is pivotal for a better visual outcome. Increased blood pressure on its own cannot fully clarify the development of retinal alterations, therefore an additional pathogenetic mechanism, such as oxidative stress, might be inquired. The aim of the study was to evaluate the changes in the level of ischemia modified albumin (IMA) in the serum and tears of HR patients in order to establish the predictive value of IMA for the HR progression. Methods. Serum and tear samples for the measurement of IMA were collected from 90 patients detected primarily with HR, who were not taking any antihypertensive or other drug that could influence the results of the study, divided according to the Keith-Wagener classification into GI ‒ 36 patients with HR grade I, GII ‒ 35 with HR grade II and GIII ‒ 19 with HR grade III. Serum and tear IMA levels were assessed using the Co2+ binding method (Gudumac V. et al., 2009) and expressed as median and interquartile range. Kruskal-Wallis and Mann-Whitney nonparametric tests were used to compare the groups and the Spearman correlation coefficient was calculated (SPSS 23.0), with p<0.05 being statistically significant. Results. The groups showed a statistically significant difference in serum IMA (p=0.006), the values increasing in parallel with the progression of HR. The serum IMA level in GII increased compared to GI (+3%; 239.06 µM/L (IQR 75.58) vs 231.77 µM/L (IQR 104.09), p=1.00), as well as in GIII patients compared to GII (+17%; 277.67 µM/L (IQR 88.72) vs 239.06 µM/L (IQR 75.58), p=0.04). There were no differences in IMA content (p=0.160), between groups in the tears. No correlations were found between serum and tear IMA levels (p=0.134), but serum IMA showed a significant moderate strength, positive correlation with the degree of HR (r=0.307**, p=0.003). Conclusion. A progressive enhancement in serum IMA level as HR advanced was identified. Thereby, the results suggest the potential relevance of serum IMA as a sensitive and early biomarker useful for grading and optimal treatment of the patients with HR.

show abstract

Section: Discussionmentioning

confidence: 97%

Study of ischemia modified albumin (IMA) as a biomarker in hypertensive retinopathy

Pavlovschi¹,

Pantea²,

Borovic³

et al. 2021

Medicine and Pharmacy Reports

Self Cite

View full text Add to dashboard Cite

show abstract

Ischemia-Modified Albumin as a Predictor Tissue Ischemia Marker in Patients With Acute Coronary Syndrome

Zuhaib,

Abid,

Uqaili

et al. 2024

PJMD

View full text Add to dashboard Cite

Background: Ischemia-modified albumin (IMA) has gained attention as an important biochemical marker of oxidative stress in acute myocardial ischemia. This study assessed the screening ability of IMA in acute coronary syndrome and its correlation with the severity of obesity, arterial blood pressure, and lipid profile. Methods: A cross-sectional study using a non-probability sampling technique with 200 patients was conducted at the Physiology Department of Liaquat University of Medical and Health Science (LUMHS) from 1st September 2021 to 1 May 2022. Obese patients from the general population who had a positive family history of cardiovascular disorders were recruited and a biophysical examination was conducted. Afterward, 5cc of blood was drawn and sent for laboratory assessment of IMA and Lipid profile by using ELISA-based assay kits. Using SPSS v.25, ANOVA and student's T-test were used to assess the quantitative data. The Chi-Square Test was employed to assess the qualitative data, and a p<0.05 was considered significant. Results: Among 200 participants, 86 participants had increased IMA. Median body mass index (BMI), high-density lipoprotein, low-density lipoproteins, triacylglycerol, cholesterol and ischemia-modified albumin was 39.00(5.00)kg/m2, 29.00(22.25)mg/dL, 165.00(75.00)mg/dL, 189.00(94.25)mg/dL, 294.50(91.75)mg/dL and 111.00(35.00)IU/mL, respectively. A strong relationship of IMA was seen with low-density lipoproteins (r=0.608), triacylglycerol (r=0.680), and cholesterol (r=0.646). An even stronger correlation was observed between ischemia-modified albumin and both systolic and diastolic blood pressure (r=0.903 and 0.839, respectively). Conclusion: IMA levels are altered with changes in BMI, lipid profile, and arterial blood pressure. Thus, IMA can be utilized to predict the risk of cardiovascular diseases in high-risk patients. Keywords: Myocardial Infarction, Cardiovascular diseases, Hypertension, Oxidative stress.

show abstract

Ischemia modified albumin in experimental ovarian torsion with and without controlled reperfusion

Cited by 2 publications

References 22 publications

Study of ischemia modified albumin (IMA) as a biomarker in hypertensive retinopathy

Study of ischemia modified albumin (IMA) as a biomarker in hypertensive retinopathy

Ischemia-Modified Albumin as a Predictor Tissue Ischemia Marker in Patients With Acute Coronary Syndrome

Contact Info

Product

Resources

About